ASH and ISTH sought to develop clinical practice guidelines on anticoagulant prophylaxis for pediatric patients who are at risk of VTE.

A little over a year after reabsorbing its anticoagulant abelacimab, Novartis has now terminated two phase 3 trials for the ...

Novel agent abelacimab has potential to be a safer anticoagulant, according to the randomized AZALEA-TIMI 71 trial. The trial had been stopped early because of a surprisingly large reduction in bleeds ...

MADRID -- Stopping oral anticoagulation after successful ablation for atrial fibrillation (AF, Afib) improved outcomes for patients without documented recurrence, the randomized ALONE-AF trial showed.

Recommendations for anticoagulant prophylaxis for pediatric patients at risk for venous thromboembolism (VTE) have been presented.

And then there were four. Late Thursday the FDA announced that it had approved edoxaban, the new oral anticoagulant manufactured by Daiichi Sankyo. The drug will be marketed under the brand name of ...

Anticoagulant therapy for ischaemic stroke aims to prevent recurrent ischaemic stroke and venous thromboembolism. Several large clinical trials have provided insight into the safety and efficacy of ...

ANTICOAGULANT treatment is winning for itself a firm place in the armamentarium against postoperative venous thrombosis and pulmonary embolism. This has been accomplished by the sheer weight of ...

High discontinuation rates of OACs in NVAF patients, with 47% stopping within 120 days, highlight adherence challenges. DOACs show a lower risk of discontinuation compared to warfarin, suggesting ...

The net clinical benefit of anticoagulants for atrial fibrillation (AF) -- one of the most important causes of irregular heartbeats and a leading cause of stroke -- decreases with age, as the risk of ...